{"@type": "dcat:Dataset", "accessLevel": "public", "bureauCode": ["009:25"], "contactPoint": {"@type": "vcard:Contact", "fn": "NIH/NCBI Data Team", "hasEmail": "mailto:info@ncbi.nlm.nih.gov"}, "description": "The present invention provides a method of treating prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I) wherein R<SUP>1 </SUP>and R<SUP>2 </SUP>are each independently hydrogen or C<SUB>1</SUB>-C<SUB>4 </SUB>alkyl; or a pharmaceutically acceptable salt thereof. In a second embodiment, the invention provides a method of treating androgen-independent prostatic adenocarcinoma comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof. In a third embodiment, the invention provides a method of treating an AKT-mediated disease selected from the group consisting of glioblastoma, colon cancer, pancreatic cancer, ovarian cancer, endometrial cancer, and renal cell cancer, comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.", "distribution": [{"@type": "dcat:Distribution", "description": "Access the complete Patent AT-E400268-T1: [Translated] BISINDOLYLMALEIMIDE FOR THE TREATMENT OF PROSTATE CANCER AND ACT-MEDIATED DISEASES on the official website.", "downloadURL": "https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400268-T1", "mediaType": "text/html", "title": "Official Data Source"}], "identifier": "https://healthdata.gov/api/views/daks-4rnw", "issued": "2025-09-05", "keyword": ["chemistry", "innovation", "patent", "pubchem", "research"], "landingPage": "https://healthdata.gov/d/daks-4rnw", "modified": "2025-09-06", "programCode": ["009:066"], "publisher": {"@type": "org:Organization", "name": "National Center for Biotechnology Information (NCBI)"}, "theme": ["NIH"], "title": "Patent AT-E400268-T1: [Translated] BISINDOLYLMALEIMIDE FOR THE TREATMENT OF PROSTATE CANCER AND ACT-MEDIATED DISEASES"}